Scientists at UC San Francisco have developed a powerful new cancer therapy that remains inactive until it reaches the brain, where it switches on to attack deadly tumors. The engineered immune cells, called B-SYNC CAR-T cells, completely eliminated diffuse midline glioma (DMG), an aggressive childhood brain cancer that is almost always fatal within a year, in two mouse models.